Immunotoxin Therapy in Treating Patients With Advanced Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignancy, including one of the following:
• * Malignant mesothelioma
• * Ovarian epithelial carcinoma (mucinous or nonmucinous), including primary peritoneal or fallopian tube carcinoma
• * Tumors that may have originated in the bowel (e.g., appendiceal carcinoma) and involve the ovary
• * Ovarian cancers of other histology are eligible provided they express mesothelin
• * Pancreatic cancer
• * Squamous cell lung cancer
• * Squamous cell cancer of the head and neck
• * Squamous cell cancer of the cervix
• Recurrent unresectable disease after prior standard anticancer therapy that was expected to prolong survival and improve quality of life OR unwilling to receive standard anticancer therapy
• At least 30% of initial or recurrent tumor cells positive (at least 1+) for mesothelin by immunohistochemistry
• Measurable or evaluable disease
• No known CNS or spinal cord involvement
• No clinically significant pericardial effusion
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 75,000/mm\^3
• Hepatic:
• Bilirubin no greater than upper limit of normal (ULN)
• AST and ALT no greater than 2.5 times ULN
• Albumin at least 3.0 g/dL
• Hepatitis B and C negative
• Renal:
• Creatinine no greater than ULN OR
• Creatinine no greater than 2.0 mg/dL if creatinine clearance at least 50 mL/min
• Calcium no greater than ULN
• Cardiovascular:
• No New York Heart Association class II-IV heart disease
• Pulmonary:
• Oxygen saturation (SO\_2) more than 92% on room air
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No detectable antibody to SS1(dsFv)-PE38
• No infection requiring parenteral antibiotics
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 1 week since prior hematopoietic growth factor therapy
• Chemotherapy:
• Not specified
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• Not specified
• Other:
• At least 4 weeks since any prior antitumor therapy and recovered
• No other concurrent antitumor therapy